Cargando…
Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors
Proteasome inhibitors (PIs) can preferentially restore bone in bone-defective lesions of patients with multiple myeloma (MM) who respond favorably to these drugs. Most prior in vitro studies on PIs used continuous exposure to low PI concentrations, although pharmacokinetic analysis in patients has s...
Autores principales: | Nakaue, Emiko, Teramachi, Jumpei, Tenshin, Hirofumi, Hiasa, Masahiro, Harada, Takeshi, Oda, Asuka, Inoue, Yusuke, Shimizu, So, Higa, Yoshiki, Sogabe, Kimiko, Oura, Masahiro, Hara, Tomoyo, Sumitani, Ryohei, Maruhashi, Tomoko, Yamagami, Hiroki, Endo, Itsuro, Tanaka, Eiji, Abe, Masahiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284934/ https://www.ncbi.nlm.nih.gov/pubmed/37039914 http://dx.doi.org/10.1007/s12185-023-03601-2 |
Ejemplares similares
-
Mechanical unloading aggravates bone destruction and tumor expansion in myeloma
por: Tanimoto, Kotaro, et al.
Publicado: (2021) -
The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2
por: Higa, Yoshiki, et al.
Publicado: (2023) -
TGF‐β‐activated kinase‐1 inhibitor LL‐Z1640‐2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF‐α and RANKL expression
por: Tenshin, Hirofumi, et al.
Publicado: (2022) -
Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma
por: Watanabe, Keiichiro, et al.
Publicado: (2021) -
TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma
por: Teramachi, Jumpei, et al.
Publicado: (2020)